Risk Control & Aggregate Reporting Service

Overview

In the high-stakes world of anti-obesity drug development, individual safety reports are only pieces of a much larger puzzle. To maintain a favorable benefit-risk profile, sponsors must synthesize vast amounts of data into cohesive, regulatory-compliant summaries. Protheragen provides a specialized risk control & aggregate reporting service, transforming disparate pharmacovigilance data into structured periodic reports such as development safety update reports (DSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs). By integrating advanced safety platforms and risk management matrices, we ensure that your therapeutic candidate meets the stringent transparency and safety standards of the FDA, EMA, and other global authorities.

Comprehensive Safety Synthesis, Ensuring Compliance - Global Aggregate Reporting for Metabolic Research

Protheragen offers an automated, high-fidelity infrastructure for the aggregation and analysis of safety data across all stages of development. We help you transition from reactive case management to proactive risk oversight through data-driven reporting.

ICH-Compliant Aggregate Report Generation

We specialize in the development of PBRER and DSUR that adhere to ICH E2C(R2) and E2F standards. Our systems automatically integrate data from the Safety Monitoring & Signal Management Service to provide a unified overview of a drug's safety status. To support this, we offer:

Real-Time Safety Dashboard

Our reporting tools feature advanced visualization dashboards designed specifically for safety teams. These dashboards enable comprehensive monitoring of the frequency and severity of adverse events (AEs) across various populations, such as elderly individuals or diabetic cohorts. By utilizing these sophisticated tools, safety teams can ensure that potential signals are captured promptly, allowing for proactive risk management. This capability is crucial in identifying trends that may emerge within different demographic groups, thus facilitating timely interventions before they can adversely affect the progression of clinical trials.

Regulatory Submission Support

We ensure that all aggregate reports are meticulously formatted for immediate inclusion in the Dossier Preparation & Submission Service. This meticulous attention to detail not only streamlines the process but also significantly facilitates a smooth path through the Regulatory Lifecycle & Inspection Support Service. By adhering to the specific requirements of regulatory authorities, we help eliminate potential delays and roadblocks that could arise during the submission process.

Workflow

Protheragen employs a standardized, automated workflow to ensure that safety reports are not only accurate but also delivered within strict regulatory windows. Our methodology emphasizes data traceability and cross-functional alignment, ensuring that medical, regulatory, and statistical teams are synchronized during the report creation process. By leveraging a centralized safety database, we eliminate the silos that often lead to inconsistent safety narratives.

Fill Out Inquiry Forms to Receive Actionable Clinical Operations Consultation.

Applications

• Global Clinical Trial Oversight

Automatically consolidating safety data from multi-center trials into a single DSUR. This allows sponsors to provide a unified safety profile to multiple regulatory agencies simultaneously, ensuring consistency in global drug development.

• High-Risk Metabolic Monitoring

Managing the risk control matrix for GLP-1 receptor agonists or other metabolic modulators. By specifically tracking risks like acute pancreatitis or biliary events, we ensure these are adequately disclosed and evaluated in annual safety updates.

• Real-World Data (RWD) Integration

Incorporating data from the post-market & real-world study service and spontaneous reporting databases (e.g., FAERS) into the PSUR. This supports the detection of rare adverse events in larger, more diverse patient populations.

• Vulnerable Population Safety Assessment

Utilizing aggregate data to identify safety trends in specific subgroups, such as the elderly or patients with metabolic syndrome, provides the evidence needed for specialized labeling or dose adjustments.

Advantages

Comprehensive Clinical Research Solutions

Protheragen provides an integrated analytical and safety framework designed to protect the integrity of your metabolic research. Our reporting services are designed to work in tandem with our data management and biostatistical platforms, ensuring that every safety conclusion is backed by a rock-solid evidence base.

Publication Data

Request a Comprehensive Strategic Consultation Supporting Integrated Product Development Path.

Customer Review

Frequently Asked Questions

1. What is the difference between a DSUR and a PBRER?

   The DSUR focuses on the safety of a drug during its clinical development phase, while the PBRER is a post-marketing report that evaluates the ongoing risk-benefit balance once the drug is on the market.

2. How frequently must DSURs and PBRERs be submitted?

   DSURs are submitted annually during clinical development, while PBRERs are submitted at defined intervals post-approval as required by ICH E2C(R2) and regional regulatory guidelines.

3. What is included in an RMP for anti-obesity therapies?

   An RMP includes safety specifications, pharmacovigilance plans, and risk minimization measures tailored to metabolic risks such as gastrointestinal events, gallbladder disease, and cardiovascular outcomes.

4. How do you handle data privacy in aggregate reports?

   Our systems include built-in de-identification and data masking protocols. We ensure that all patient-level data is summarized and anonymized in accordance with GDPR and HIPAA requirements before the reports are generated.

Protheragen is committed to turning safety data into strategic clarity. Whether you are preparing for a global launch or enhancing your risk management strategies, our reporting experts ensure your risk control is second to none. Contact us today to streamline your aggregate reporting process.